BioNTech (Group)

http://www.biontech.de

Twitter: @BioNTech_Group

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *

	Start	2008-01-01 established
	Predecessor	University of Mainz (Johannes Gutenberg University)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	cancer test
	Person	Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
	Person 2	Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)

	Region	Mainz
	Country	Germany
	Street	12 An der Goldgrube
	City	55131 Mainz
	Tel	+49-6131-9084-0
		Address record changed: 2019-09-16

Basic data	Employees	D: 101 to 500 (2014-10-01)
	Currency	EUR
	Annual sales	108,589,000 (revenues, consolidated (2019) 2019-12-31)
	Profit	-179,172,000 (2019-12-31)
	Cash	451,597,000 (2020-03-31)

		* Document for ï¿½About Sectionï¿½: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz.

		Record changed: 2020-09-26